• 1龍泉驛區(qū)第一人民醫(yī)院內(nèi)分泌代謝科（成都，610100）;2成都中醫(yī)藥大學(xué)內(nèi)分泌科;3新津縣人民醫(yī)院內(nèi)分泌科;

目的 　探討Grave病患者采用131I治療前后血清中白細(xì)胞介素-2（IL-2）及白細(xì)胞介素-12 p40（IL-12p40）含量的改變及細(xì)胞因子在該疾病中的作用與意義。 方法 　采用酶聯(lián)免疫吸附試驗(yàn)雙抗夾心法、放射免疫法，對(duì)2009年10月－2011年12月收治的28例Grave病患者（治療組）經(jīng)131I治療前后血清中IL-2和IL-12p40含量進(jìn)行自身對(duì)比及與健康志愿者（對(duì)照組）對(duì)比；同時(shí)對(duì)治療組患者治療前、后的血清游離三碘甲腺原氨酸（FT3）、血清游離甲狀腺素（FT4）、促甲狀腺激素（TSH）水平與對(duì)照組進(jìn)行對(duì)比。 結(jié)果 　治療后患者血清中IL-2和IL-12p40的水平為（19.54 ± 11.17）、（615.88 ± 349.32） ng/mL，明顯高于治療前（P＜0.05），且與對(duì)照組比較差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）；患者治療前后血清中IL-2和IL-12p40水平與FT3、FT4水平有顯著相關(guān)性。 結(jié)論 　血清IL-2和
IL-12p40可能共同參與Grave病的發(fā)病過(guò)程，并且這兩種因子的水平與FT3、FT4水平呈負(fù)相關(guān)性。

引用本文： 鐘莉,陳秋,楊廷強(qiáng). 131碘治療Grave病患者血清中白細(xì)胞介素-2、白細(xì)胞介素-12p40蛋白水平改變及臨床意義. 華西醫(yī)學(xué), 2012, 27(9): 1335-1337. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《華西醫(yī)學(xué)》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. 　Zhang NY, Zhao BQ, Nan Y, et al. Changes of thyroid function before and after metabolic control in diabetics[J]. Fourth Mil Med University, 1998, 19(3): 302-304.
2. 　Molnar I. The balance shift in Thl/Th2 related IL-12/IL-5 eytokines in Graves’disease dufng methimazole therapy[J]. Autoimmunity, 2007, 40(1): 31-37．.
3. 　Natt N, Bahn RS. Cytokinesintheevolution gravesophthalmopathy[J]. Autoimmunity, 1997, 26(2): 129-136.
4. 　楊吉生, 薛蘭芳, 胡明造, 等. Graves病碘-131治療的劑量計(jì)算[J]. 云南醫(yī)藥, 1996, 17(1): 2-4.
5. 　楊吉生, 王強(qiáng), 胡明造, 等. 131I治療Graves病的最適劑量探討[J]. 同位素, 2000, 12(3): 177-181.
6. 　Brent GA. Graves’ disease[J]. N Engl J Med, 2008, 358: 2594-605.
7. 　InoueA, Koizumi S, MatsudaA, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
8. 　Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive Immunity[J]. Nat Rev Immunol, 2003, 3: 133-46.
9. 　池沛冬, 李麗, 范艷瑩, 等. IL-12恢復(fù)并促進(jìn)氟尿嘧啶抑制的T細(xì)胞免疫功能[J]. 癌癥, 2007, 26(8): 801-808.
10. 　謝建平, 吳成秀, 嚴(yán)宗遜, 等. Graves病治療前后細(xì)胞因子水平的變化[J]. 中華核醫(yī)學(xué)雜志, 2004, 24(4): 247-249.
11. 　朱明風(fēng), 溫赤君, 錢紅. 131I治療Graves病的轉(zhuǎn)歸與三種細(xì)胞因子的關(guān)系[J].標(biāo)記免疫分析與臨床, 2007, 14(3): 150-152.
12. 　ColinIM, Isaac J, Dupret P, et al. Adenovirus-mediated interleukin-12 gene,transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in penca tumor-bearing mice BMC[J] . Cancer, 2005, 5: 51.
13. 　Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves’disease: effectof treatment, thyroid function, ophthalmopathy and cigarette smoking[J]. Eur Endocrinol, 2000, 143(2): 197-202.
14. 　InoueA, Koizumi S, Matsuda A, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
15. 　梁馳, 何鳳屏, 曾建業(yè), 等. Grave’s病患者血清中IFN-γ、TNF-α和IL-6的變化[J]. 廣西醫(yī)學(xué), 2008, 30(8): 1146-1147.
16. 　何長(zhǎng)武, 黃鶯, 王社教. 甲亢患者131碘治療前后細(xì)胞因子水平的變化分析[J]. 陜西醫(yī)學(xué)雜志, 2011, 40(11): 1493-1494.
17. 　湯建林, 李玉瑩, 高柳艷, 等. 131I治療Graves病療效評(píng)價(jià)[J]. 醫(yī)學(xué)理論與實(shí)踐, 2011, 24(13): 1551-1552.
18. 　李春北. IL-2與IL-10濃度變化對(duì)Graves病治療效果的預(yù)測(cè)[J]. 重慶醫(yī)科大學(xué)學(xué)報(bào), 2010, 3(3): 412-414.
  1. 1. 　Zhang NY, Zhao BQ, Nan Y, et al. Changes of thyroid function before and after metabolic control in diabetics[J]. Fourth Mil Med University, 1998, 19(3): 302-304.
  2. 2. 　Molnar I. The balance shift in Thl/Th2 related IL-12/IL-5 eytokines in Graves’disease dufng methimazole therapy[J]. Autoimmunity, 2007, 40(1): 31-37．.
  3. 3. 　Natt N, Bahn RS. Cytokinesintheevolution gravesophthalmopathy[J]. Autoimmunity, 1997, 26(2): 129-136.
  4. 4. 　楊吉生, 薛蘭芳, 胡明造, 等. Graves病碘-131治療的劑量計(jì)算[J]. 云南醫(yī)藥, 1996, 17(1): 2-4.
  5. 5. 　楊吉生, 王強(qiáng), 胡明造, 等. 131I治療Graves病的最適劑量探討[J]. 同位素, 2000, 12(3): 177-181.
  6. 6. 　Brent GA. Graves’ disease[J]. N Engl J Med, 2008, 358: 2594-605.
  7. 7. 　InoueA, Koizumi S, MatsudaA, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
  8. 8. 　Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive Immunity[J]. Nat Rev Immunol, 2003, 3: 133-46.
  9. 9. 　池沛冬, 李麗, 范艷瑩, 等. IL-12恢復(fù)并促進(jìn)氟尿嘧啶抑制的T細(xì)胞免疫功能[J]. 癌癥, 2007, 26(8): 801-808.
  10. 10. 　謝建平, 吳成秀, 嚴(yán)宗遜, 等. Graves病治療前后細(xì)胞因子水平的變化[J]. 中華核醫(yī)學(xué)雜志, 2004, 24(4): 247-249.
  11. 11. 　朱明風(fēng), 溫赤君, 錢紅. 131I治療Graves病的轉(zhuǎn)歸與三種細(xì)胞因子的關(guān)系[J].標(biāo)記免疫分析與臨床, 2007, 14(3): 150-152.
  12. 12. 　ColinIM, Isaac J, Dupret P, et al. Adenovirus-mediated interleukin-12 gene,transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in penca tumor-bearing mice BMC[J] . Cancer, 2005, 5: 51.
  13. 13. 　Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves’disease: effectof treatment, thyroid function, ophthalmopathy and cigarette smoking[J]. Eur Endocrinol, 2000, 143(2): 197-202.
  14. 14. 　InoueA, Koizumi S, Matsuda A, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
  15. 15. 　梁馳, 何鳳屏, 曾建業(yè), 等. Grave’s病患者血清中IFN-γ、TNF-α和IL-6的變化[J]. 廣西醫(yī)學(xué), 2008, 30(8): 1146-1147.
  16. 16. 　何長(zhǎng)武, 黃鶯, 王社教. 甲亢患者131碘治療前后細(xì)胞因子水平的變化分析[J]. 陜西醫(yī)學(xué)雜志, 2011, 40(11): 1493-1494.
  17. 17. 　湯建林, 李玉瑩, 高柳艷, 等. 131I治療Graves病療效評(píng)價(jià)[J]. 醫(yī)學(xué)理論與實(shí)踐, 2011, 24(13): 1551-1552.
  18. 18. 　李春北. IL-2與IL-10濃度變化對(duì)Graves病治療效果的預(yù)測(cè)[J]. 重慶醫(yī)科大學(xué)學(xué)報(bào), 2010, 3(3): 412-414.